{
    "name": "ioflupane I 123",
    "comment": "Rx",
    "other_names": [
        "DaTscan"
    ],
    "classes": [
        "Iodinated Contrast Media"
    ],
    "source": "https://reference.medscape.com/drug/datscan-ioflupane-i-123-999618",
    "pregnancy": {
        "common": [
            "Radioactive iodine products cross the placenta and can permanently impair fetal thyroid function; administration of an appropriate thyroid blocking agent is recommended before use in a pregnant woman to protect the woman and fetus from accumulation of iodine",
            "There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; advise pregnant women of potential risks of fetal exposure to radiation doses with administration of product"
        ],
        "specific": [
            {
                "type": "Animal data",
                "description": [
                    "Animal reproduction studies have not been conducted with ioflupane I 123; all radiopharmaceuticals have the potential to cause fetal harm depending on fetal stage of development and magnitude of radiation dose; administration at a dose of 185 MBq (5 mCi) results in an absorbed radiation dose to uterus of 0.3 rad (3.0 mGy)",
                    "Radiation doses >15 rad (150 mGy) have been associated with congenital anomalies but doses under 5 rad (50 mGy) generally have not"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "Iodide 123 (I 123), the radionuclide, is present in human milk; there is no information on effects on breastfed infant or on milk production; advise a lactating woman to interrupt breastfeeding and pump and discard breastmilk for at least 6 days (>10 physical half-lives) after administration in order to minimize radiation exposure to a breastfed infant"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to active substance, excipients, or iodine"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause hypersensitivity reactions depicted by skin erythema and pruritus; these reactions have generally occurred within minutes of administration and have either resolved spontaneously or following administration of corticosteroids and antihistamines; contraindicated with known hypersensitivity to ioflupane I 123; have treatment measures available and monitor patients for symptoms or signs of a hypersensitivity reaction",
                "Thyroid accumulation of iodine-123 may occur; to decrease thyroid accumulation of Iodine-123, block the thyroid gland (eg, potassium iodide) before administration of therapy; failure to block thyroid uptake of I-123 may result in an increased long-term risk for thyroid neoplasia"
            ],
            "specific": [
                {
                    "type": "Radiation risk",
                    "description": [
                        "Contributes to patientâ€™s overall long-term cumulative radiation exposure and its associated increased risk for cancer ",
                        "Ensure safe handling to minimize radiation exposure to patients and clinicians ",
                        "Bladder protection",
                        "Minimize radiation dose to bladder by encouraging hydration before and following administration",
                        "Encourage patient to void frequently for first 48 hr following administration "
                    ]
                },
                {
                    "type": "Drug interaction overview ",
                    "description": [
                        "Drugs that bind to dopamine transporter with high affinity may interfere with image ",
                        "Effects of dopamine agonists and antagonists on ioflupane I 123 imaging have not been established ",
                        "Drugs that may interfere with ioflupane binding include ",
                        "Amoxapine, amphetamine, armodafinil, benztropine, bupropion, buspirone, cocaine, mazindol, methamphetamine, methylphenidate, norephedrine, phentermine, phenylpropanolamine, selegiline, and sertraline",
                        "Drugs that may increase or decrease ioflupane binding include ",
                        "Citalopram and paroxetine "
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benztropine",
            "description": {
                "common": "benztropine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buspirone",
            "description": {
                "common": "buspirone decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "cocaine topical decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "dextroamphetamine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iodixanol",
            "description": {
                "common": "iodixanol decreases effects of ioflupane I 123 by unknown mechanism. Use Caution/Monitor. Administration of iodinated contrast agents may interfere with thyroid uptake of radioactive iodine (I-131 and I-123) and decrease therapeutic and diagnostic efficacy in patients with thyroid carcinoma. Decreased efficacy lasts for 6-8 weeks. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "ioflupane I 123 increases toxicity of metformin by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Administration of intravascular iodinated contrast agents in metformin-treated patients has led to rare cases of acute decrease in renal function and the occurrence of lactic acidosis. The American College of Radiology Guidelines (2018) recommend temporarily stopping metformin in patients with eGFR is <30 mL/min/1.73 m2 or who are undergoing arterial catheter studies that might result in emboli to the renal arteries. Continue to withhold metformin for 48 hr subsequent to the procedure and reinstituted only after renal function has been reevaluated and found to be normal. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "methamphetamine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "norepinephrine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentermine",
            "description": {
                "common": "phentermine decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline decreases effects of ioflupane I 123 by receptor binding competition. Use Caution/Monitor. Drugs that bind to dopamine transporter receptor with high affinity may interfere with the image following ioflupane I 123 administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voclosporin",
            "description": {
                "common": "voclosporin, ioflupane I 123.\nEither increases toxicity of the other by nephrotoxicity and/or ototoxicity. Modify Therapy/Monitor Closely. Coadministration with drugs associated with nephrotoxicity may increase the risk for acute and/or chronic nephrotoxicity."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Vertigo",
            "percent": null
        },
        {
            "name": "Xerostomia",
            "percent": null
        },
        {
            "name": "Immune system disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "including dyspnea",
            "percent": null
        },
        {
            "name": "edema",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "erythema",
            "percent": null
        },
        {
            "name": "and pruritus",
            "percent": null
        },
        {
            "name": "General disorders and administration site conditions",
            "percent": null
        },
        {
            "name": "Injection site pain",
            "percent": null
        }
    ]
}